BioInvent Receives €2 Million Milestone Payment From Daiichi Sankyo For Licensed N-CoDeR Antibody Progressing Into Phase I Clinical Trial
LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent International (BINV) (STO:BINV) today announced that it will receive a €2 million milestone payment under the collaboration with Daiichi Sankyo pertaining to the progression of an anti-FGFR4 antibody into a Phase I clinical trial in the EU.
The anti-FGFR4 antibody, known as U3-1784, was discovered by Daiichi Sankyo utilizing BioInvent’s n-CoDeR® phage display library. Its target indication is for solid cancer tumors.
The anti-FGFR4 antibody, known as U3-1784, was discovered by Daiichi Sankyo utilizing BioInvent’s n-CoDeR® phage display library. Its target indication is for solid cancer tumors.